Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zhejiang Anglikang Pharma Approved for $87 Million IPO in Shenzhen

publication date: Sep 24, 2018

Zhejiang Anglikang Pharmaceutical, headquartered in Shengzhou, has been approved to stage an $87 million IPO on the Shenzhen SME (small- and medium-sized enterprise) Exchange. The company is mainly known as a cephalosporin manufacturer with an annual capacity of 1500 tons. It also makes angiography and gastrointestinal drugs. Founded in 1994, Anglikang produces finished drugs, APIs and empty gelatin capsules and has annual revenues of over $150 million. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital